Related Experiment Video
Updated: Aug 14, 2026
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
Rescue RM/CS-AKI by blocking strategy with one-dose anti-myoglobin RabMAb
Xinyue Wang1,2,3, Ning Li4,5,6,7, Lu Han8,9
1School of Disaster and Emergency Medicine, Faculty of Medicine, Tianjin University, No. 92 Weijin Road, Nankai District, Tianjin, 300072, China.
Abstract:
Rhabdomyolysis or Crush syndrome-related AKI (RM/CS-AKI) has high mortality, and there is no effective early on-site treatment method. The critical pathogenic factor of RM/CS-AKI is the excessive free myoglobin (Mb) in blood circulation. Here, based on the concept of creating a "mobile barrier", we develop an anti-Mb rabbit monoclonal antibody (RabMAb) with high specificity, affinity, stability, and broad species reactivity. A single dose of anti-Mb RabMAb injection is sufficient for emergency rescue in both homologous and heterologous RM/CS-AKI male animal models. The main goal of blocking the passage of free Mb through the glomerular filtration barrier has been achieved by using the anti-Mb RabMAb, which has a long-term stable therapeutic effect within 14 days and promotes phagocytosis of Mb. The optimal administration strategy, pharmacokinetic analysis, toxicity evaluation for anti-Mb RabMAb, and the distribution of its immune complexes in RM/CS-AKI mice are investigated. Thus, we develop effective prevention and control strategies for RM/CS-AKI.
Insights
Researchers developed a novel antibody to neutralize excess myoglobin (Mb) in rhabdomyolysis or crush injury-induced acute kidney injury (RM/CS-AKI). This breakthrough offers a potential early treatment to prevent kidney damage and improve survival rates in affected patients.
Area of Science:
- Nephrology
- Immunology
- Biotechnology
Background:
- Rhabdomyolysis or crush syndrome-related acute kidney injury (RM/CS-AKI) presents a significant clinical challenge with high mortality rates.
- Excessive circulating free myoglobin (Mb) is the primary driver of kidney damage in RM/CS-AKI.
- Current treatment options lack effective early, on-site interventions for RM/CS-AKI.
Purpose of the Study:
- To develop a targeted therapeutic agent for early intervention in RM/CS-AKI.
- To create a high-affinity, specific antibody capable of neutralizing free myoglobin.
- To establish a "mobile barrier" concept for preventing glomerular filtration of myoglobin.
Main Methods:
- Development of a rabbit monoclonal antibody (RabMAb) targeting free myoglobin.
- Evaluation of the anti-Mb RabMAb's specificity, affinity, stability, and cross-species reactivity.
- In vivo testing of a single-dose anti-Mb RabMAb injection in homologous and heterologous RM/CS-AKI animal models.
- Assessment of the antibody's therapeutic efficacy, long-term effects (14 days), and mechanism of action (blocking glomerular passage, promoting phagocytosis).
- Pharmacokinetic analysis, toxicity evaluation, and immune complex distribution studies in RM/CS-AKI mice.
Main Results:
- A highly specific and stable anti-Mb RabMAb was successfully developed.
- A single dose of anti-Mb RabMAb demonstrated effective emergency rescue in RM/CS-AKI animal models.
- The antibody successfully blocked free myoglobin passage through the glomerular filtration barrier.
- Therapeutic effects were sustained for up to 14 days, with evidence of enhanced Mb phagocytosis.
- Pharmacokinetic and toxicity profiles were established, supporting its therapeutic potential.
Conclusions:
- The developed anti-Mb RabMAb represents a promising therapeutic strategy for RM/CS-AKI.
- This antibody-based approach offers a novel "mobile barrier" to mitigate myoglobin-induced kidney injury.
- The findings pave the way for effective prevention and control strategies against RM/CS-AKI.
